Purida WientongWallaya JongjarornprasertDuangchit PanomvanaChulalongkorn UniversityMahidol University2018-05-032018-05-032011-06-03International Journal of Pharmacy and Pharmaceutical Sciences. Vol.3, No.SUPPL. 3 (2011), 47-5009751491097514912-s2.0-79957784788https://repository.li.mahidol.ac.th/handle/123456789/12809This study is objected to determine whether 60 mg/day dose of aspirin inhibit platelet aggregation capacity adequately to be clinically effective in diabetic patients. Total 97 diabetic patients who were taking low doses of aspirin participated in the study; among these, 75 patients were taking 60 mg/day of aspirin. Besides, 32 diabetes patients who were not taking aspirin were recruited as the control group. Platelet function was assessed by optical platelet aggregation technique using arachidonic acid and ADP as agonists and serum thromboxane B 2 level was determined by enzyme immunoassay (EIA) technique. Platelet functions as assessed by optical platelet aggregation after taking 60 mg/day of aspirin did not differ from those obtained after taking 300 mg/day of aspirin. The frequency of aspirin resistance after 60 mg/day of aspirin was similar the results previously reported for higher doses of aspirin. The serum thromboxane was more than 95% inhibited after taking 60 mg/day of aspirin. Aspirin 60 mg/day may be sufficient to be used in average type 2 diabetic patients for prevention of adverse cardiovascular events.Mahidol UniversityPharmacology, Toxicology and PharmaceuticsArticleSCOPUS